Join our Webinar series on JCA-directed evidence generation planning!
Health technology assessment (HTA) is of crucial importance for the success of the market access of innovative pharmacological therapies launching in the European Union (EU). In many EU Member States, HTA decisions have a direct impact on patients' access to new therapeutic approaches and determine the extent of reimbursement by public healthcare systems. With the entry into force of the ‘Regulation 2021/2282 of the European Parliament and of 15 December 2021 the Council on health technology assessment and amending Directive 2011/24/EU’ the Joint Clinical Assessment (JCA) of health technologies is gradually being introduced as a transnational process at European level (EU HTA), starting with the evaluation of oncological therapies and Advanced Therapy Medicinal Products (ATMPs) from January 2025 onwards.
This new regulation is intended to give all EU citizens faster access to new health technologies and harmonize the available evidence in a single dossier submitted to EU-HTA agencies - but in practice, it is likely to present an additional barrier to market access. In light of this legislation, GIPAM will host a webinar series for market access professionals in the pharmaceutical industry on the implications and challenges of the upcoming JCA process.
Why join?
To find out more about the new mandatory JCA procedures that must be carried out in parallel with the authorization by the EMA.
To optimize strategies for generating evidence and potential solutions to address ad-hoc policy questions from >27 EU national stakeholders.
What do we offer?
Free access to two 2-hour webinars incl. an opportunity to ask your questions directly to our research consultants with longstanding expertise in developing HTA strategies and evidence-generation plans.
Specific content tailored to the needs of health technology developers depending on their time to product launch:
WEBINAR 1: How to do early strategic evidence generation planning under the new common EU-HTA regulation?
§ For health technology developers who plan to launch in the next 2 to 4 years
WEBINAR 2: How to plan and support the JCA dossier development?
§ For health technology developers who plan to launch within less than 2 years.
When will it run?
WEBINAR 1: On February 28th (Wednesday): 15:30 – 17:30 pm (CET)
WEBINAR 2: On March 6th (Wednesday): 16:00 – 17:30 pm (CET)
If you have any questions or are interested in a customized workshop tailored to your business case, please do not hesitate to contact us via nils.picker@gipam-health.com.
More Articles
